GAVI facts and figures

in page functions

Statistics measuring Gavi, the Vaccine Alliance's impact on global immunisation

Every year, academics, journalists, teachers and students ask for statistics detailing Gavi's results since the Vaccine Alliance was established in 2000. Sourcing the Gavi Secretariat and members of the Vaccine Alliance, including WHO, UNICEF and civil society organisations, these key facts and figures list Gavi's achievements to date as well as demonstrating the Vaccine Alliance's catalytic role within global immunisation.

65 million

Nearly 65 million children in Gavi-supported countries received three doses of a DTP-containing vaccine (including pentavalent vaccine) in 2014. This equals almost 200 million contacts with the primary health system every year and can provide a robust platform for other health interventions.

Source: WHO/UNICEF 2015

200

Gavi supported more than 200 vaccine introductions and campaigns in the 2011–2015 period – four times as many as in the previous five years.

Source: Gavi

+60

The Vaccine Alliance has helped strengthen health systems and immunisation services in more than 60 countries and increased injection safety.

Source: Gavi

1 million

Since the first human papillomavirus (HPV) vaccine demonstration project in Kenya in 2013, an estimated 1 million girls have been vaccinated with Gavi support – a figure expected to rise to 30 million by the end of 2020. Gavi has already started to fund national HPV programmes in Rwanda and Uganda.

Source: Gavi

39

In September 2014, Nepal became the first country to introduce inactivated polio vaccine (IPV) with Gavi support. By the end of 2015, 39 countries had introduced the vaccine with support from the Vaccine Alliance.

Source: Gavi

22 million

Since 2007, countries have immunised 22 million children with a 2nd dose of measles vaccine with Gavi support. Gavi-funded measles campaigns have helped vaccinate another 67 million children in countries considered at high risk of measles outbreaks.

Source: WHO/UNICEF 2015

140 million

By the end of 2014, Gavi-funded measles-rubella catch-up campaigns, targeting the next generation of mothers and children aged 9 months to 14 years, had reached 140 million people.

Source: WHO/UNICEF 2015

88 million

Starting in 2011, Gavi-supported mass prevention campaigns have protected 88 million people in 14 “high-risk” countries. We have also helped 17 countries introduce yellow fever vaccine through routine immunisation since 2000.

Source: Gavi

+600,000

Since its creation in 2013, the global oral cholera vaccine has been used to vaccinate more than 600,000 people; in 2014, doses were allocated to Ethiopia, Guinea, Haiti, Nepal and South Sudan.

Source: Gavi

US$ 80-100 billion

Investing in Gavi’s 2016-2020 strategy has the potential to deliver US$ 80-100 billion in costs averted related to illness, such as productivity loss due to death/disability, treatment costs, caretaker productivity loss and transport costs.

Source: Stack M et al. Estimated economic benefits during Decade of Vaccines, Health Affairs 2011

+220 million

By the end of 2014, 15 countries in the African meningitis belt had collectively immunised more than 220 million people against meningitis A with support from Gavi.

Source: WHO 2014

95%

Over 95% of children in Gavi-supported countries do not yet have access to all 11 vaccines recommended by WHO for infants in all countries.

Source: WHO/UNICEF 2015

Every 2 minutes

One woman dies from cervical cancer every two minutes - or 266,000 a year - over 85% in the developing world. Two-thirds of all cervical cancer deaths can be prevented with HPV vaccine.

Source: WHO

Over 7 million

Since its launch in 2000, Gavi has helped developing countries to prevent more than 7 million future deaths from hepatitis B, Haemophilus influenzae type b, human papillomavirus, Japanese encephalitis, measles, meningitis A, pneumococcal disease, rotavirus diarrhoea and yellow fever.

Source: Gavi / Bill & Melinda Gates Foundation 2015

More than 500 million

Since 2000, Gavi support has contributed to the immunisation of an additional 500 million children.

Source: WHO/UNICEF 2015

47 million

By the end of 2014, Vaccine Alliance support had contributed to immunising 47 million children against pneumococcal disease. Gavi surpassed its 2015 target of 45 introductions more than 1 year ahead of schedule. By the end of 2015, three-quarters of all Gavi-supported countries had introduced the vaccine.

Source: WHO/UNICEF 2015

+243,000,000

Gavi support helped countries to immunise close to 250 million children between 2011 and 2015.

Source: WHO/UNICEF 2015

26%

Pneumonia and diarrhoea account for 26% of deaths in under-fives in Gavi-supported countries.

Source: CHERG-WHO 2014

+70

In 2014, more than 70 countries were co-financing new and underused vaccines supplied by Gavi. Their contributions totalled over US$ 80 million. More than 20 countries are projected to be fully self-financing their vaccines by 2020.

Source: Gavi

US$ 10 billion

As of the end of November 2015, Gavi’s total commitments amount to over US$ 10 billion. This includes current commitments from year 2000 up to 2020 for both country programmes and investment cases.

Source: Gavi

+20 million

Vaccine Alliance support has contributed to immunising over 20 million children against rotavirus diarrhoea. By the end of 2015, more than half of all Gavi-supported countries had introduced the vaccine.

Source: WHO/UNICEF 2015

3.9 million

The Vaccine Alliance’s support for vaccines contributed to averting nearly 4 million future deaths between 2011 and 2015.

Source: Gavi, the Vaccine Alliance/Bill & Melinda Gates Foundation 2015

+40%

The weighted average price of pentavalent vaccine per dose has dropped from US$ 3.56 in 2003 to US$ 1.90 in 2014.

Source: Gavi

1.5 million

In 2012, approximately 6.6 million children died before the age of five. WHO estimates that 1.5 million of these deaths are due to vaccine-preventable diseases.

Source: WHO

5 -> 15

From 5 to 15 vaccine manufacturers supplying Gavi – from 1 to 8 based in emerging markets.

2001: 5 vaccine manufacturers - 1 based in an emerging market;
Mid 2015: 15 vaccine manufacturers – 8 based in emerging markets.

Source: Gavi

19 million

Nearly 19 million infants remain under-immunised with three doses of diphtheria-tetanus-pertussis vaccine in the world each year. One in five of all children in Gavi-supported countries miss out on this basic package of vaccines.

Source: WHO/UNICEF 2015

close icon

modal window here